Genmab (NASDAQ:GMAB) Azioni

GENMAB A/S -SP ADR

Genmab

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab AS

News

ARAI

Arrive AI Receives Approval To List Its Shares On Nasdaq Under Symbol ARAI; To Begin Trading On May 15, 2025

Needham analyst Ryan Koontz reiterates Planet Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>) with a Buy and maintains $8 price target.

Price Target

Reiteration

Analyst Ratings

Needham Reiterates Buy on Planet Labs, Maintains $8 Price Target

V2X Collaborates With Bell Textron To Begin Strategic Planning For U.S. Army's Flight School Next Program

Fidelity National Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNF#NYSE">FNF</a>) has outperformed the market over the past 5 years by 1.87% on an annualized basis producing an average annual return of 16.9%. Currently, Fidelity National Finl has a market capitalization of $15.60 billion. 
Buying $100 In FNF: If an investor had bought $100 of FNF stock 5 years ago, it would be worth $215.81 today based on a price of $56.79 for FNF at the time of writing.
<h3>Fidelity National Finl's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747240311_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $100 Invested In Fidelity National Finl 5 Years Ago Would Be Worth Today

VRTX

Live On CNBC, Steve Weiss Announces Sold Vertex Pharmaceuticals

Keefe, Bruyette &amp; Woods analyst Sanjay Sakhrani maintains Nayax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYAX#NASDAQ">NYAX</a>) with a Market Perform and raises the price target from $38 to $40.

NYAX

Keefe, Bruyette & Woods Maintains Market Perform on Nayax, Raises Price Target to $40

Live On CNBC, Steve Weiss Announces Bought More UnitedHealth Group

<a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-pheochromocytoma-or-paraganglioma#:~:text=On%20May%2014%2C%202025%2C%20the,an%20oral%20therapy%20for%20PPGL" title="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-pheochromocytoma-or-paraganglioma#:~:text=On%20May%2014%2C%202025%2C%20the,an%20oral%20therapy%20for%20PPGL">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-pheochromocytoma-or-paraganglioma#:~:text=On%20May%2014%2C%202025%2C%20the,an%20oral%20therapy%20for%20PPGL</a>.

Biotech

General

Reported Earlier: 'FDA Approves Belzutifan For Pheochromocytoma Or Paraganglioma' - FDA

BMO Capital analyst Simeon Siegel maintains Under Armour (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>) with a Outperform and lowers the price target from $12 to $9.

BMO Capital Maintains Outperform on Under Armour, Lowers Price Target to $9

WIIM

CAE shares are trading lower after the company reported mixed Q4 financial results.

<a href="https://www.bleeckerstreetresearch.com/research/aurora-innovation-aur" title="https://www.bleeckerstreetresearch.com/research/aurora-innovation-aur">https://www.bleeckerstreetresearch.com/research/aurora-innovation-aur</a>

Short Sellers

Watching Aurora Innovation; Bleecker Street Research Issues Report On Co

BMO Capital analyst Simeon Siegel maintains American Eagle Outfitters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEO#NYSE">AEO</a>) with a Market Perform and lowers the price target from $15 to $11.

BMO Capital Maintains Market Perform on American Eagle Outfitters, Lowers Price Target to $11

BMO Capital analyst Keith Bachman maintains Okta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) with a Market Perform and raises the price target from $130 to $135.

OKTA

BMO Capital Maintains Market Perform on Okta, Raises Price Target to $135

BMO Capital analyst James Thalacker maintains NRG Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) with a Market Perform and raises the price target from $115 to $167.

BMO Capital Maintains Market Perform on NRG Energy, Raises Price Target to $167

BMO Capital analyst Keith Bachman maintains ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) with a Outperform and raises the price target from $1025 to $1150.

BMO Capital Maintains Outperform on ServiceNow, Raises Price Target to $1150

Millrose Properties shares are trading higher after the company reported Q1 financial results and raised its FY25 guidance for new transaction funding outside of the Lennar Master program.

JOET

iShares Trust Barclays 20+ Year Treasury Bond Fund

Live On CNBC, Joe Terranova Announces Sold Entire iShares 20+ Year Treasury Bond ETF Position

WING

Wingstop shares are trading higher after multiple firms raised their respective price targets on the stock.

Shares of Under Armour Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>) were declining in early trading on Wednesday, after the company Tuesday reported its <a href="https://www.benzinga.com/25/05/45383247/under-armour-tops-q4-sales-estimates-details-here">fiscal fourth-quarter results</a>.
Here are some key analyst takeaways.
<ul class="wp-block-list">
<li>Truist Securities <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/655796fc7f07f10001c9da96/joseph-civello">analyst Joseph Civello</a> reaffirmed a Buy rating, while reducing the price target from $9 to $7.</li>
<li>Stifel <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58beb7e7b85e93000190633d/jim-duffy">analyst Jim Duffy</a> maintained a Buy rating, while cutting the price target from $11 to $10.</li>
<li>Needham <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5846ee56ee7bf6000154d12e/tom-nikic">analyst Tom Nikic</a> reiterated a Hold rating on the stock.</li>
</ul>
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Truist Securities: Under Armour reported its fiscal fourth-quarter results broadly in line with expectations while providing mixed guidance. Lower promotions led to gross margin expansion, he added.
The company projected sales to decline by 4%-5% in the fiscal first quarter, coming in well below the prior consensus estimate of 1.6% growth, the analyst stated. "While we believe the company's efforts to elevate the brand's positioning are prudent, tariff-driven uncertainty makes us incrementally cautious on their ability to drive full-priced demand higher," he further wrote.
Stifel: Under Armour reported quarterly revenue of $1.18 billion, slightly above consensus of $1.16 billion, Duffy said. Gross margin expanded by 170 basis points to 46.7%, beating Street's 46.0% estimates, he added.
The company's year-on-year improvement was driven by "supply chain benefits including lower product and freight costs, favorable pricing, and positive impacts from product mix and FX, partially offset by an unfavorable channel and regional mix," the analyst wrote. Management guided to adjusted earnings of 1-3 cents per share for the fiscal first quarter, better than the Street's prior breakeven estimate, he further stated.
Needham: Under Armour's results were marginally better than expected, although its revenues are yet to bottom, Nikic said. With the company lowering discounts, revenues declined again, following an almost 10% downturn last year, he added.
The analyst stated that it is yet to be seen whether Under Armour's upcoming product seasons will "bear fruit on the top line. &#8221; Management expects revenue to decline 4%- 5% in the fiscal first quarter.
UAA Price Action: Shares of Under Armour had declined by 0.56% to $6.24 at the time of publication on Wednesday.
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45262278/under-armour-faces-tough-road-ahead-says-analyst">Under Armour Faces Tough Road Ahead, Says Analyst</a></li>
</ul>
Image: Shutterstock

Analyst Color

Earnings

Under Armour Finds No Major Surprises In Q4, Analysts Cut Price Target

IPOs

ETOR

Etoro Group IPO Opens For Trade At $69.69/Share; IPO Priced At $52/Share On 11,923,018 Shares

Press Releases

Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.

TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025

Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress

Comments

Genmab

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO